Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

David L. Lacey, Emma Timms, Hong‐Lin Tan et al. · Cell · 1998 · 5.5K citations · Full text

Medicine, Cell Biology, Bone Metabolism +13

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Hisataka Yasuda, Nobuyuki Shima, N. Nakagawa et al. · Proceedings of the National Academy of Sciences · 1998 · 4.3K citations

Medicine, Cell Biology, Molecular Biology +15

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Steven R. Cummings, Javier San Martín, Michael R. McClung et al. · New England Journal of Medicine · 2009 · 3.4K citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts

Hiroshi Takayanagi, Sunhwa Kim, Takako Koga et al. · Developmental Cell · 2002 · 2.7K citations · Full text

Medicine, Cell Biology, Molecular Biology +16

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Karim Fizazi, Michael A. Carducci, Matthew R. Smith et al. · The Lancet · 2011 · 2K citations · Full text

Medicine, Oncology, Urology +17